Fc-optimized CD40 agonistic antibody elicits tertiary lymphoid structure formation and systemic antitumor immunity in metastatic cancer
Cancer Cell · 2025-10 · 43 (10) · 1902-1916.e9
DOI: 10.1016/j.ccell.2025.07.013 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Cancer Cell, 2025-10. Verfasst von Juan C Osorio und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Laboratory of Molecular Genetics and Immunology, Rockefeller…. Hauptthemen laut MEDLINE: CD40 Antigens, Tertiary Lymphoid Structures, Antibodies, Monoclonal, Immunoglobulin Fc Fragments. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NCATS NIH HHS, Breast Cancer Alliance.
Abstract (Originalsprache)
CD40 agonism enhances antitumor immunity but is limited by systemic toxicity and poor efficacy. Here, we present a phase 1 study (NCT04059588) of intratumoral (i.t.) 2141-V11, an Fc-engineered anti-CD40 agonistic antibody with enhanced binding to the inhibitory receptor FcγRIIB. Among 12 metastatic cancer patients, 2141-V11 was well tolerated without dose-limiting toxicities. Six patients experienced tumor reduction, including two complete responses in melanoma and breast cancer. 2141-V11 induced regression in injected and non-injected lesions, correlating with systemic CD8+ T cell activation and mature tertiary lymphoid structures (TLSs) in complete responders. In CD40/FcγRs humanized mice bearing orthotopic tumors, i.t. 2141-V11 promoted de novo TLS formation, facilitating i.t. CD8+ T cell effector responses independent of lymph node priming. The resulting local immune responses by 2141-V11 mediated abscopal antitumor effects and sustained immune memory. These findings demonstrate that i.t. 2141-V11 is safe and promotes immune-privileged tumor microenvironments that promote systemic and durable antitumor immunity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Laboratory of Molecular Genetics and Immunology, Rockefeller University, New York, NY 10065, USA. Electronic address: osorioj@mskc…
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Laboratory of Molecular Genetics and Immunology, Rockefeller University, New York, NY 10065, USA.
- Laboratory of Molecular Genetics and Immunology, Rockefeller University, New York, NY 10065, USA.
- Laboratory of Molecular Genetics and Immunology, Rockefeller University, New York, NY 10065, USA; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
- Bio-Imaging Resource Center, Rockefeller University, New York, NY 10065, USA.
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Förderung
- NCI NIH HHS
- NCATS NIH HHS
- Breast Cancer Alliance
- Arnold and Mabel Beckman Foundation
- National Center for Advancing Translational Sciences
- National Institutes of Health National Cancer Institute
- Debra and Leon Black Family Foundation
- National Institutes of Health
Zitieren
APA
Osorio, J. C., Knorr, D. A., Weitzenfeld, P., Blanchard, L., Yao, N., Baez, M., Sevilla, C., DiLillo, M., Rahman, J., Sharma, V. P., Bromberg, J., Postow, M. A., Ariyan, C., Robson, M. E., & Ravetch, J. V. (2025). Fc-optimized CD40 agonistic antibody elicits tertiary lymphoid structure formation and systemic antitumor immunity in metastatic cancer. Cancer Cell, 43(10), 1902-1916.e9. https://doi.org/10.1016/j.ccell.2025.07.013
Vancouver
Osorio JC, Knorr DA, Weitzenfeld P, Blanchard L, Yao N, Baez M, et al. Fc-optimized CD40 agonistic antibody elicits tertiary lymphoid structure formation and systemic antitumor immunity in metastatic cancer. Cancer Cell. 2025;43(10):1902-1916.e9. doi:10.1016/j.ccell.2025.07.013
BibTeX
@article{Osorio2025,
author = {Osorio, Juan C and Knorr, David A and Weitzenfeld, Polina and Blanchard, Lucas and Yao, Ning and Baez, Maria and Sevilla, Carlo and DiLillo, Meghan and Rahman, Jahan and Sharma, Ved P and Bromberg, Jacqueline and Postow, Michael A and Ariyan, Charlotte and Robson, Mark E and Ravetch, Jeffrey V},
title = {Fc-optimized CD40 agonistic antibody elicits tertiary lymphoid structure formation and systemic antitumor immunity in metastatic cancer},
journal = {Cancer Cell},
year = {2025},
volume = {43},
number = {10},
pages = {1902--1916.e9},
doi = {10.1016/j.ccell.2025.07.013}
}
EUVIMED